Tell me detail explanation on ketamine
Reading File
Finding Sources
Searching PubMed
ketamine pharmacology clinical use
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive data from multiple authoritative textbooks. Let me compose the full detailed answer.
Ketamine - Comprehensive Overview
1. Introduction and Classification
Ketamine is a phencyclidine (PCP) derivative and the only intravenous anesthetic still widely used that produces "dissociative anesthesia." It is classified as:
- A dissociative anesthetic / analgesic
- A non-competitive NMDA receptor antagonist
- A Schedule III controlled substance (USA)
- A "club drug" in recreational contexts (street names: "Special K," "Vitamin K," "Ket")
- An FDA-approved antidepressant in its S-enantiomer form (esketamine/Spravato)
Commercially available formulations contain a racemic mixture of (S)- and (R)-ketamine enantiomers. The S(+) enantiomer is roughly 3-4 times more potent than the R(-) isomer as an anesthetic and has greater effects on cerebral metabolism. Esketamine (S-ketamine only) is approved specifically for depression.
- Katzung's Basic and Clinical Pharmacology, 16th Ed.
- Miller's Anesthesia, 10th Ed.
2. Mechanism of Action
Ketamine's pharmacology is multireceptor and complex:
Primary Mechanism
- Non-competitive NMDA receptor antagonism (open-channel blocker): Ketamine enters and blocks the NMDA receptor channel when it is open ("use-dependent"). Unlike many other NMDA antagonists, it does not compete with glutamate at the binding site - instead, it physically occludes the open channel. This is key to its dissociative and analgesic effects.
Secondary Mechanisms
| Receptor/Target | Effect |
|---|---|
| Opioid receptors (μ, δ, κ) | Contributes to analgesia |
| Muscarinic receptors | Antagonism (contributes to salivation, tachycardia) |
| Monoamine reuptake | Blocks reuptake of norepinephrine, dopamine, serotonin (sympathomimetic effects) |
| σ1 receptors | Binding contributes to psychotomimetic effects |
| AMPA receptors | Hydroxynorketamine (active metabolite) activates AMPA receptors - proposed antidepressant pathway |
| Voltage-gated Na+ / Ca2+ channels | Membrane-stabilizing, local anesthetic-like effect |
Antidepressant Mechanism (current understanding)
The antidepressant mechanism is still debated but leading hypotheses include:
- NMDA antagonism increases BDNF (brain-derived neurotrophic factor) synthesis
- Hydroxynorketamine (HNK), an active metabolite, stimulates AMPA receptors independent of NMDA blockade
- Ketamine dampens burst activity of neurons in the lateral habenula (a "disappointment/anti-reward" center), which disinhibits the ventral tegmental area (dopamine reward system)
- Ketamine mobilizes Gsa proteins from lipid rafts, amplifying cAMP signaling and BDNF production rapidly
- Katzung's Basic and Clinical Pharmacology, 16th Ed.
- Kaplan & Sadock's Comprehensive Textbook of Psychiatry
- Neuroscience: Exploring the Brain, 5th Ed.
3. Pharmacokinetics
| Parameter | Detail |
|---|---|
| Solubility | Partially water-soluble and highly lipid-soluble |
| Onset (IV) | ~1 minute |
| Onset (IM) | ~3-5 minutes |
| Duration (IV) | 5-15 minutes (dissociative state); full recovery 50-110 min |
| Duration (IM) | 15-30 minutes; recovery 60-140 min |
| Distribution | Rapid CNS uptake due to high lipid solubility; terminates by redistribution to peripheral tissues |
| Metabolism | Hepatic, via cytochrome P450 (N-demethylation) → Norketamine (active, 1/3 to 1/5 potency) → hydroxylated/conjugated inactive metabolites |
| Excretion | Urinary (inactive metabolites) |
| Protein binding | Low (unique among IV anesthetics) |
| Route flexibility | IV, IM, oral, rectal, intranasal, epidural |
| Hepatic first-pass | Substantial; oral/rectal routes require higher doses and have less predictable results |
- Katzung's Basic and Clinical Pharmacology, 16th Ed.
- Roberts and Hedges' Clinical Procedures in Emergency Medicine
4. Pharmacodynamics - Organ System Effects
4a. Central Nervous System
- Dissociative state: Disrupts thalamoneocortical-limbic pathways, preventing higher centers from perceiving painful, auditory, or visual stimuli
- Analgesia + amnesia + immobility without true unconsciousness - a unique "cataleptic" trance
- Eyes remain open with slow nystagmic gaze and moderately dilated pupils
- Increases cerebral blood flow (CBF) and cerebral metabolic rate (CMR) - the S-enantiomer substantially increases CMR; R-enantiomer tends to decrease it
- CBF increased ~14% (subanesthetic) to ~36% (anesthetic doses); CBV increased ~50%
- Autoregulation is maintained; CO2 responsiveness preserved
- Anticonvulsant: Despite myoclonic potential, ketamine is effective for refractory status epilepticus
- ICP: Historically avoided in raised ICP, but modern evidence shows ketamine is safe when combined with adjunctive sedatives (benzodiazepines, propofol). Decreases in ICP have been shown with large doses in propofol-sedated patients.
- EEG: Complex - at subanesthetic doses, decreases alpha power, increases theta/gamma. At anesthetic doses, large slow waves alternating with gamma bursts.
4b. Cardiovascular System
- Sympathomimetic: Stimulates CNS sympathetic outflow → increases heart rate, blood pressure, cardiac output, and myocardial oxygen consumption
- This makes ketamine useful in hemodynamically unstable / hemorrhagic shock patients
- Direct myocardial depression (intrinsic negative inotrope) - usually masked by sympathetic stimulation, but may emerge in critically ill patients with depleted catecholamine reserves
- Useful "Ketofol" combination (ketamine + propofol) reduces risk of hypotension compared to propofol alone
4c. Respiratory System
- Minimal respiratory depression - the most clinically valued property
- Respiratory response to hypercapnia is preserved
- Protective airway reflexes maintained (cough, swallow, pharyngeal/laryngeal tone)
- Bronchodilator - relaxes bronchial smooth muscle via sympathomimetic enhancement and vagal inhibition; particularly valuable in reactive airway disease and asthma
- Transient apnea possible with rapid IV bolus or large doses
- Risk of laryngospasm in children (due to hypersalivation) - monitor, don't routinely pretreat with anticholinergics
4d. Miscellaneous
-
Increased salivation and tracheobronchial secretions
-
Increased skeletal muscle tone (cataleptic state)
-
Lacrimation common
-
Nausea and vomiting post-recovery (use antiemetics such as ondansetron)
-
Miller's Anesthesia, 10th Ed.
-
Katzung's Basic and Clinical Pharmacology, 16th Ed.
-
ROSEN's Emergency Medicine; Roberts and Hedges' Clinical Procedures
5. Dosing
Adult Dosing
| Indication | Route | Dose |
|---|---|---|
| Anesthesia induction | IV | 1-2 mg/kg |
| Anesthesia induction | IM | 4-6 mg/kg |
| Procedural sedation (PSA) | IV | 1-2 mg/kg (dissociative state in ~1 min) |
| Procedural sedation | IM | 4-5 mg/kg |
| Sub-dissociative analgesia | IV bolus | 0.2-0.8 mg/kg |
| Analgesia infusion | IV infusion | 3-5 mcg/kg/min (subanalgesic) |
| Anesthesia maintenance | IV infusion | 15-45 mcg/kg/min + 50-70% N2O |
| RSI (intubation adjunct) | IV | 1-2 mg/kg over 1 min |
Pediatric Dosing (Harriet Lane Handbook, 23rd Ed.)
| Route | Dose |
|---|---|
| IV | 0.5-1 mg/kg (max 150 mg/dose) |
| IM | 2-5 mg/kg |
| PO | 5 mg/kg |
| Intranasal (≥3 months) | 3-6 mg/kg (split between nostrils via atomizer) |
Administration note: IV ketamine must be given slowly (over 30-60 seconds or 0.5 mg/kg/min) to minimize risk of apnea, laryngospasm, and emergence phenomena.
6. Clinical Uses
| Setting | Application |
|---|---|
| Emergency Medicine | Procedural sedation and analgesia (PSA), RSI, excited delirium management |
| Anesthesia | Induction and maintenance, especially hemodynamically unstable patients; adjunct to regional anesthesia |
| Pediatrics | Gold-standard for brief painful procedures; fracture reduction, laceration repair, burn dressing changes |
| Critical Care | Sedation, bronchospasm treatment, status epilepticus (refractory) |
| Psychiatry | IV ketamine / intranasal esketamine for treatment-resistant depression (TRD) and acute suicidality |
| Pain Management | Opioid-sparing multimodal analgesia, chronic pain, perioperative analgesia |
| Pre-hospital / Field | Used by military medics and EMS due to analgesic potency and hemodynamic stability |
| Reactive Airways | Asthma exacerbation intubation, bronchospasm |
7. Adverse Effects / Side Effects
Emergence Phenomenon (most notable)
- Occurs in ~15% of patients; characterized by vivid/unpleasant dreams, hallucinations, out-of-body experiences, sensory distortions
- Significant agitation in <1-2% of patients
- More common in: adult females, adolescents/adults vs. children, patients with psychiatric disorders
- Treatment: Benzodiazepines (diazepam/midazolam) during recovery phase
- Prevention: Quiet, low-stimulation recovery; benzodiazepine premedication not routinely recommended unless treating pre-procedural anxiety
Other Adverse Effects
| Effect | Notes |
|---|---|
| Nausea/vomiting | Common post-recovery; treat with ondansetron |
| Hypersalivation | Can contribute to laryngospasm; anticholinergic not routinely recommended |
| Laryngospasm | Rare; more common in children; avoid rapid IV injection |
| Transient apnea | Rare; more common with rapid large IV bolus |
| Hypertension/tachycardia | Due to sympathetic stimulation; avoid in severe hypertension |
| Increased ICP | Theoretical (largely refuted with adjunctive sedation) |
| Psychomimetic effects | Hallucinations, vivid dreams (basis for recreational misuse) |
| Chronic use toxicity | Ketamine-induced uropathy (bladder/upper urinary tract damage), cognitive impairment |
8. Contraindications
Absolute
- Patients in whom significant increases in blood pressure would be dangerous (e.g., aortic dissection, hypertensive emergency, intracranial hemorrhage with uncontrolled hypertension)
- Known hypersensitivity to ketamine
- Schizophrenia or active psychosis (may exacerbate psychotic symptoms)
Relative
- Raised intracranial pressure (use with adjunctive sedation if necessary)
- Thyroid disorder / thyrotoxicosis (potentiates catecholamine effects)
- Cardiovascular disease with elevated workload risk (severe CAD)
- Age <3 months
- Procedures involving the posterior pharynx (airway reflexes maintained but stimulation can trigger laryngospasm)
- Intraocular pressure concerns (glaucoma, penetrating eye injury) - ketamine increases IOP
9. Ketamine in Psychiatry - Antidepressant Use
Approved Formulations
- IV ketamine (racemic): Off-label; used in specialty infusion centers for treatment-resistant depression (TRD) and acute suicidal ideation
- Intranasal esketamine (Spravato): FDA-approved (2019) for TRD and major depressive disorder with acute suicidality. Administered in a certified healthcare setting with 2-hour monitoring.
Clinical Profile
-
Onset of antidepressant effect: within hours (vs. weeks for SSRIs/SNRIs)
-
Duration: A single infusion provides relief for up to 1-2 weeks
-
Effective in patients who have failed multiple traditional antidepressants
-
Limitation: Effect is transient and wears off with repetitive use; dependency risk
-
Kaplan & Sadock's Comprehensive Textbook of Psychiatry
-
Katzung's Basic and Clinical Pharmacology, 16th Ed.
10. Recreational Misuse and Toxicity
- Sold illicitly as "Special K," "Vitamin K," or "Ket" - white crystalline powder, liquid, capsules
- Can be snorted, swallowed, injected, or smoked
- Effects at recreational doses: dissociation, euphoria, visual/auditory hallucinations, "k-hole" (severe dissociation at high doses), out-of-body experience
- Psychedelic effects last ~1 hour
- Does not produce physical dependence/addiction in the same way as opioids (relative addiction risk = 1), but chronic use causes:
- Ketamine-induced uropathy: ulcerative cystitis, contracted bladder, upper urinary tract damage
- Cognitive impairment (memory, attention)
- Long-lasting psychosis (especially with PCP, less so ketamine)
- Toxicity review: Schep et al., Clin Toxicol 2023 (PMID 37267048)
11. Special Considerations
Ketofol
Combination of ketamine + propofol. Ketamine's sympathomimetic and bronchodilatory effects offset propofol's hypotension and respiratory depression. Used as an induction agent in hemodynamically borderline patients.
Ketamine in Asthma / Bronchospasm
Particularly valuable for RSI in acute severe asthma: bronchodilates while maintaining hemodynamics. First-line induction agent for intubation in bronchoconstriction.
Pediatric Advantage
Children tolerate ketamine better than adults - lower incidence of emergence reactions, generally safer procedural sedation profile. Standard of care for painful ED procedures in children.
Pregnancy / Obstetrics
Small subanesthetic IV boluses (0.2-0.8 mg/kg) provide useful supplemental analgesia during regional anesthesia (e.g., caesarean section with inadequate spinal block) without significant neonatal effects at these doses.
Summary Table
| Property | Ketamine |
|---|---|
| Class | Dissociative anesthetic, NMDA antagonist |
| Primary receptor | NMDA (non-competitive, open-channel blocker) |
| Analgesia | Profound |
| Respiratory depression | Minimal |
| Cardiovascular | Stimulatory (sympathomimetic) |
| Airway reflexes | Preserved |
| CNS | Increases CBF + CMR; anticonvulsant at therapeutic doses |
| Key advantage | Analgesia + hemodynamic stability + bronchodilation |
| Key disadvantage | Emergence reactions, psychomimetic effects, increased secretions |
| Antidepressant use | Yes (esketamine FDA-approved; IV ketamine off-label for TRD) |
| Abuse potential | Moderate (Schedule III) |
Sources: Miller's Anesthesia (10th Ed.) | Katzung's Basic and Clinical Pharmacology (16th Ed.) | ROSEN's Emergency Medicine | Roberts and Hedges' Clinical Procedures in Emergency Medicine | Harriet Lane Handbook (23rd Ed.) | Kaplan & Sadock's Comprehensive Textbook of Psychiatry | Neuroscience: Exploring the Brain (5th Ed.)
Recent evidence: Johnston et al. (2024, PMID 37340091) and Kim et al. (2024, PMID 37729028) provide updated reviews of ketamine's neuropsychiatric mechanisms. Schep et al. (2023, PMID 37267048) covers clinical toxicology comprehensively.
This is a shared conversation. Sign in to Orris to start your own chat.